BRPI0916931A2 - agentes terapêuticos - Google Patents
agentes terapêuticosInfo
- Publication number
- BRPI0916931A2 BRPI0916931A2 BRPI0916931A BRPI0916931A BRPI0916931A2 BR PI0916931 A2 BRPI0916931 A2 BR PI0916931A2 BR PI0916931 A BRPI0916931 A BR PI0916931A BR PI0916931 A BRPI0916931 A BR PI0916931A BR PI0916931 A2 BRPI0916931 A2 BR PI0916931A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic agents
- therapeutic
- agents
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8570508P | 2008-08-01 | 2008-08-01 | |
| US9856208P | 2008-09-19 | 2008-09-19 | |
| PCT/US2009/052449 WO2010014930A2 (en) | 2008-08-01 | 2009-07-31 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0916931A2 true BRPI0916931A2 (pt) | 2015-11-24 |
Family
ID=41170025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0916931A BRPI0916931A2 (pt) | 2008-08-01 | 2009-07-31 | agentes terapêuticos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110165183A1 (pt) |
| EP (1) | EP2324020A2 (pt) |
| JP (1) | JP2011529918A (pt) |
| KR (1) | KR20110050654A (pt) |
| CN (1) | CN102171211A (pt) |
| AU (1) | AU2009276420A1 (pt) |
| BR (1) | BRPI0916931A2 (pt) |
| CA (1) | CA2732628A1 (pt) |
| IL (1) | IL210990A0 (pt) |
| MX (1) | MX2011001259A (pt) |
| NZ (1) | NZ590922A (pt) |
| RU (1) | RU2011105768A (pt) |
| WO (1) | WO2010014930A2 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077346A1 (es) | 2009-07-31 | 2011-08-17 | Biocryst Pharm Inc | Compuestos heterociclicos como inhibidores de janus quinasa |
| KR20130083389A (ko) * | 2010-05-28 | 2013-07-22 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 야누스 키나아제 억제제로서 헤테로사이클릭 화합물 |
| CN103502249A (zh) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
| CN104220435A (zh) | 2012-03-13 | 2014-12-17 | 巴斯夫欧洲公司 | 杀真菌的嘧啶化合物 |
| CA2882367C (en) | 2012-09-10 | 2021-11-09 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| CA2890201A1 (en) * | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| US9481679B2 (en) * | 2012-12-17 | 2016-11-01 | Sun Pharmaceutical Industries Limited | Process for the preparation of tofacitinib and intermediates thereof |
| EP2938616A4 (en) * | 2012-12-28 | 2016-06-15 | Glenmark Pharmaceuticals Ltd | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES |
| WO2015036058A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| CA2925211A1 (en) * | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EP2994454B1 (en) * | 2013-12-09 | 2019-03-06 | Unichem Laboratories Limited | An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine |
| JP6504548B2 (ja) | 2014-02-21 | 2019-04-24 | プリンシピア バイオファーマ インコーポレイテッド | Ｂｔｋ阻害剤の塩および固体形態 |
| CN104860950A (zh) * | 2014-02-24 | 2015-08-26 | 重庆医药工业研究院有限责任公司 | 一种制备4-氯吡咯[2,3-d]并嘧啶的方法 |
| CN104059016A (zh) * | 2014-06-20 | 2014-09-24 | 湖南天地恒一制药有限公司 | 制备托法替布的中间体及所述中间体的制备方法 |
| KR101710127B1 (ko) * | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
| MX381283B (es) | 2014-12-18 | 2025-03-12 | Principia Biopharma Inc | Tratamiento de pénfigo. |
| CN105732637B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP3078665A1 (en) * | 2015-04-10 | 2016-10-12 | OLON S.p.A. | Efficient method for the preparation of tofacitinib citrate |
| HK1250159A1 (zh) | 2015-06-22 | 2018-11-30 | 小野药品工业株式会社 | Brk抑制性化合物 |
| WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN105622616A (zh) * | 2016-02-25 | 2016-06-01 | 上海雅本化学有限公司 | 一种4-氯吡咯并嘧啶的制备方法 |
| CA3028169A1 (en) | 2016-06-29 | 2018-01-04 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| EP3782998B1 (en) * | 2018-04-16 | 2023-05-10 | Shenzhen TargetRx, Inc. | Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof |
| US20210106584A1 (en) | 2019-10-14 | 2021-04-15 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| CN116768908A (zh) * | 2022-03-10 | 2023-09-19 | 石家庄迪斯凯威医药科技有限公司 | 一种含n多环化合物及其制备方法与用途 |
| CN117164519A (zh) * | 2023-08-18 | 2023-12-05 | 杭州小蓓医药科技有限公司 | 一种l-肌肽的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2219018T3 (es) * | 1998-06-19 | 2004-11-16 | Pfizer Products Inc. | Compuestos de pirrolo(2,3-d)pirimidina. |
| TR200201498T2 (tr) * | 1999-12-10 | 2003-01-21 | Pfizer Products Inc. | Pirrolo [2,3-d] pirimidin bileşikleri. |
| CN100351253C (zh) * | 2000-06-26 | 2007-11-28 | 辉瑞产品公司 | 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物 |
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| CA2507392A1 (en) * | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| BRPI0409903A (pt) * | 2003-04-29 | 2006-04-25 | Pfizer Ltd | 5,7-diamino-pirazol[4,3-d]pirimidina úteis no tratamento de hipertensão |
| BRPI0416909A (pt) * | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | método de tratamento de aterosclerose |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2007007919A2 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| NL2000291C2 (nl) * | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
| TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| SG189837A1 (en) * | 2010-10-08 | 2013-06-28 | Abbvie Inc | FURO[3,2-d]PYRIMIDINE COMPOUNDS |
-
2009
- 2009-07-31 MX MX2011001259A patent/MX2011001259A/es unknown
- 2009-07-31 AU AU2009276420A patent/AU2009276420A1/en not_active Abandoned
- 2009-07-31 BR BRPI0916931A patent/BRPI0916931A2/pt not_active IP Right Cessation
- 2009-07-31 JP JP2011521361A patent/JP2011529918A/ja active Pending
- 2009-07-31 KR KR1020117004724A patent/KR20110050654A/ko not_active Withdrawn
- 2009-07-31 EP EP09791064A patent/EP2324020A2/en not_active Withdrawn
- 2009-07-31 CN CN2009801396041A patent/CN102171211A/zh active Pending
- 2009-07-31 WO PCT/US2009/052449 patent/WO2010014930A2/en active Application Filing
- 2009-07-31 NZ NZ590922A patent/NZ590922A/xx not_active IP Right Cessation
- 2009-07-31 US US13/057,100 patent/US20110165183A1/en not_active Abandoned
- 2009-07-31 CA CA2732628A patent/CA2732628A1/en not_active Abandoned
- 2009-07-31 RU RU2011105768/04A patent/RU2011105768A/ru not_active Application Discontinuation
-
2011
- 2011-02-01 IL IL210990A patent/IL210990A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2324020A2 (en) | 2011-05-25 |
| AU2009276420A1 (en) | 2010-02-04 |
| NZ590922A (en) | 2012-09-28 |
| RU2011105768A (ru) | 2012-09-10 |
| CA2732628A1 (en) | 2010-02-04 |
| WO2010014930A3 (en) | 2010-07-29 |
| MX2011001259A (es) | 2011-03-15 |
| US20110165183A1 (en) | 2011-07-07 |
| JP2011529918A (ja) | 2011-12-15 |
| IL210990A0 (en) | 2011-04-28 |
| WO2010014930A2 (en) | 2010-02-04 |
| CN102171211A (zh) | 2011-08-31 |
| KR20110050654A (ko) | 2011-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0916931A2 (pt) | agentes terapêuticos | |
| DK2144905T3 (da) | Terapeutiske midler | |
| EP2296593A4 (en) | MEDICAL HEAD COVER | |
| EP2263545A4 (en) | sonographer | |
| GB0811304D0 (en) | Therapeutic agents | |
| BRPI0807137A2 (pt) | Agentes antiparasitários | |
| DK2178568T3 (da) | Kontrastmidler | |
| BRPI0913945A2 (pt) | agentes anti-inflamatórios | |
| EP2052011A4 (en) | TARGETED THERAPEUTIC AGENT POLYLYSIN DENDRIMER | |
| DK2035369T3 (da) | Terapeutiske | |
| DK2185142T3 (da) | Antiseptiske midler | |
| HUE036071T2 (hu) | Macitentánt tartalmazó terápiás készítmények | |
| BRPI0920743A2 (pt) | ribonucleases terapeuticas | |
| LT3150178T (lt) | Stimuliavimo aparatas | |
| BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| BRPI0910722A2 (pt) | columbário | |
| GB0812309D0 (en) | Therapeutic agents | |
| GB0805818D0 (en) | Therapeutic agents | |
| BRPI0818598A2 (pt) | agentes terapêuticos - 802 | |
| GB0801081D0 (en) | Therapeutic agents | |
| GB0801080D0 (en) | Therapeutic agents | |
| HRP20160577T1 (hr) | Liječenje osteoartritisa | |
| EP2309854A4 (en) | ACCELERATED THERAPY: | |
| BRPI0909764A2 (pt) | compostos terapêuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2373 DE 28-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |